INTREXON CORP
CIK 1356090 · SVP, Consumer Sector · last filed 2018-09-28
INTREXON CORP is a SVP, Consumer Sector who has filed 36 SEC Form 4 insider transactions across 7 companies since 2011. The most recent filing, for ZIOP, was dated Sep 28, 2018. Across all open-market trades the lifetime net is +$174.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $982 across reported positions. The firm reports its address in Germantown, MD. 232 SEC filings were submitted jointly with RANDAL J KIRK.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$982
7
36
$174.12M
Filer Profile
GERMANTOWN, MD 20876
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Alaunos Therapeutics, Inc. (ZIOP) Delisted | 10%+ Owner | 198,259 | $0.87 | $171.6K | $80.18M | 24 | 2018-09-28 |
| Fibrocell Science, Inc. (FCSC) Delisted | 10%+ Owner | 1,154,725 | — | — | $29.20M | 3 | 2017-12-13 |
| SOLIGENIX, INC. (SNGXW) Delisted | 10%+ Owner | 101,171 | $0.01 | $911 | -$1.00M | 1 | 2017-05-08 |
| AQB | 10%+ Owner | 539 | $1.22 | $658 | $50.02M | 1 | 2017-01-20 |
| Armata Pharmaceuticals, Inc. (APHB) Delisted | 10%+ Owner | 48,155 | — | — | -$168.8K | 2 | 2016-12-29 |
| PRECIGEN, INC. (XON) Delisted | SVP, Consumer Sector | — | — | — | $0 | 2 | 2016-01-26 |
| OGEN | 10%+ Owner | 679 | $0.48 | $325 | $15.89M | 2 | 2015-12-03 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-09-28 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
| 2018-08-31 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
| 2018-07-31 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
| 2018-04-30 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
| 2018-03-30 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
| 2018-02-28 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
| 2018-01-31 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
| 2017-12-13 | Fibrocell Science, Inc. (FCSC) Delisted | Buy (P) | +5,454,546 | $4.20M | EDGAR |
| 2017-11-30 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
| 2017-11-01 | Alaunos Therapeutics, Inc. (ZIOP) Delisted | Other (J) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.